Comparison
|
Platinum/Pemetrexed vs. Platinum/Docetaxel
| | |
Platinum/Pemetrexed vs. Platinum/Paclitaxel
| | |
Platinum/Pemetrexed vs. Platinum/Gemcitabine
| | |
Platinum/Pemetrexed vs. Platinum/Vinorelbine
| | |
---|
Matched pairs
|
95
|
RR
|
P value*
|
118
|
RR
|
P value*
|
199
|
RR
|
P value*
|
72
|
RR
|
P value*
|
---|
Measured outcomes
|
N
|
Mean/%
|
STDEV
|
N
|
Mean/%
|
STDEV
| | |
N
|
Mean/%
|
STDEV
|
N
|
Mean/%
|
STDEV
| | |
N
|
Mean/%
|
STDEV
|
N
|
Mean/%
|
STDEV
| | |
N
|
Mean/%
|
STDEV
|
N
|
Mean/%
|
STDEV
| | |
---|
Treatment pattern
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Completed treatment cycles
|
95
|
3.4
|
1.7
| |
95
|
2.9
|
1.7
|
0.028
|
118
|
3.6
|
1.7
|
118
|
2.9
|
1.6
| |
0.006
|
199
|
3.6
|
1.7
|
199
|
2.7
|
1.5
| |
<0.001
|
72
|
3.3
|
1.7
|
72
|
2.5
|
1.3
| |
0.003
|
Length of hospital stay per cycle (days)
|
95
|
10.1
|
6.7
|
95
|
11.5
|
8.2
| |
0.191
|
118
|
10.4
|
6.1
|
118
|
13.5
|
11.7
| |
0.011
|
199
|
10.9
|
6.0
|
199
|
15.0
|
7.0
| |
<0.001
|
72
|
13.1
|
7.2
|
72
|
16.9
|
8.5
| |
0.001
|
Tumor response based on RECIST (%)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
PR
|
13
|
13.7%
| |
13
|
13.7%
| |
1.000
|
1.000
|
22
|
18.6%
| |
6
|
5.1%
| |
3.647
|
0.002
|
36
|
18.1%
| |
18
|
9.1%
| |
1.989
|
0.007
|
16
|
22.2%
| |
9
|
12.5%
| |
1.776
|
0.108
|
SD
|
44
|
46.3%
| |
29
|
30.5%
| |
1.518
|
0.025
|
45
|
38.1%
| |
32
|
27.1%
| |
1.406
|
0.074
|
72
|
36.2%
| |
52
|
26.1%
| |
1.387
|
0.043
|
28
|
38.9%
| |
18
|
25.0%
| |
1.556
|
0.077
|
PD
|
9
|
9.5%
| |
13
|
13.7%
| |
0.693
|
0.371
|
11
|
9.3%
| |
21
|
17.8%
| |
0.522
|
0.059
|
24
|
12.1%
| |
23
|
11.6%
| |
1.043
|
0.879
|
7
|
9.7%
| |
12
|
16.7%
| |
0.581
|
0.197
|
Unknown
|
29
|
30.5%
| |
40
|
42.1%
| |
0.724
|
0.101
|
40
|
33.9%
| |
59
|
50.0%
| |
0.678
|
0.020
|
67
|
33.7%
| |
106
|
53.3%
| |
0.632
|
<0.001
|
21
|
29.2%
| |
33
|
45.8%
| |
0.638
|
0.029
|
Other tumor response outcomes (%)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Early treatment discontinuation
|
45
|
47.4%
| |
62
|
65.3%
| |
0.726
|
0.007
|
52
|
44.1%
| |
71
|
60.2%
| |
0.732
|
0.022
|
91
|
45.7%
| |
135
|
67.8%
| |
0.674
|
<0.001
|
38
|
52.8%
| |
55
|
76.4%
| |
0.691
|
0.007
|
Tumor control
|
57
|
60.0%
| |
42
|
44.2%
| |
1.357
|
0.029
|
67
|
56.8%
| |
38
|
32.2%
| |
1.764
|
<0.001
|
108
|
54.3%
| |
70
|
35.2%
| |
1.543
|
<0.001
|
44
|
61.1%
| |
20
|
27.5%
| |
2.222
|
0.005
|
Treatment failure
|
38
|
40.0%
| |
53
|
55.8%
| |
0.717
|
0.029
|
51
|
43.2%
| |
80
|
67.8%
| |
0.637
|
<0.001
|
91
|
45.7%
| |
129
|
64.8%
| |
0.705
|
<0.001
|
28
|
38.9%
| |
45
|
72.5%
|
0.537
| |
0.005
|
- STDEV, standard deviation; RR, rate ratio; RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; SD, stable disease; PD, progressive disease. *: P values less than 0.05 were in bold to indicate significant differences.